Trial site
ETG Lublin Sp. z o.o.
Lublin, 20-412, PolandEU-13 widening countryNot linked to an institution yet
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 26 trials
- Phase 11 trial
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Not yet recruiting5 trials
- Suspended1 trial
- Lead sponsor
- argenx2 trials
- H. Lundbeck A/S2 trials
- Janssen Research & Development, LLC2 trials
- Merz Therapeutics GmbH2 trials
- EMD Serono Research & Development Institute, Inc.1 trial
- and 10 more
Running trials
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2025-525022-35-00· Phase 3· Hunan Mabgeek Biotech Co. Ltd.· Source
Not yet recruiting
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
NCT07760818· Phase 2· argenx· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849· Phase 3· argenx· Source
Recruiting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter
Study of Intra-Articular Allocetra in Participants with Primary Knee
Osteoarthritis.
2025-524668-39-00· Phase 2· Enlivex Therapeutics Ltd.· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Not yet recruiting
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source
Recruiting
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865· Phase 3· Vor Biopharma· Source
Active, not recruiting
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
NCT07284901· Phase 3· Kailera· Source
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial-1)
2025-521315-39-00· Phase 1· Grey Wolf Therapeutics Limited· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713· Phase 3· Merz Therapeutics GmbH· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700· Phase 3· Merz Therapeutics GmbH· Source
Recruiting
A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· Phase 2· Inmagene LLC· Source
Active, not recruiting
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
NCT05164172· Phase 3· H. Lundbeck A/S· Source
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
NCT04965675· Phase 3· H. Lundbeck A/S· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error